Scientists launch biobank to unlock secrets of rare vasculitis

NCT ID NCT05364892

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting blood, urine, and fecal samples from 100 people with ANCA-associated vasculitis, a rare autoimmune disease. Researchers will follow participants for up to 5 years, tracking relapses and complications. The goal is to identify factors that predict disease flare-ups and improve long-term management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors predict relapses and complications in ANCA vasculitis, leading to better, more personalized care.

What could go wrong

This is an observational study, not a treatment trial. It collects data and samples but does not test any new therapy, so it cannot directly improve health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHRU de Brest - Service de rhumatologie

    RECRUITING

    Brest, Brest, 29200, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••